Robotic Biobanking Systems Global Market Report 2025

The robotic biobanking systems market size has grown rapidly in recent years. It will grow from $2.0 billion in 2024 to $2.3 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. Growth in the historic period can be attributed to increasing demand for efficient biological sample management, rising volumes of biomedical research activities, the expanding establishment of biobanks and biorepositories, a growing focus on personalized medicine, and increased clinical trial activity.

The robotic biobanking systems market size is expected to see rapid growth in the next few years. It will grow to $3.99 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. Growth in the forecast period can be linked to rising adoption of precision medicine and genomics research, greater integration of automation within laboratory workflows, growing demand for large-scale population biobanking initiatives, expanding applications in biomarker discovery and translational research, and heightened emphasis on data-driven healthcare decision-making. Major trends expected in the forecast period include the integration of artificial intelligence and machine learning for sample tracking and predictive analytics, advancements in fully automated cryogenic storage systems, improvements in robotic arm precision and dexterity, implementation of Internet of Things-enabled monitoring technologies, and increased adoption of cloud-based biobanking data management platforms.

The growing volume of biological sample collections is expected to drive the expansion of the robotic biobanking systems market in the coming years. Biological sample collections involve systematically gathering and preserving materials such as blood, tissue, saliva, or other biospecimens, along with related data, for use in biomedical research, diagnostics, and therapeutic development. The increase in biological sample collections is largely fueled by the rising demand for precision medicine, as modern healthcare increasingly relies on large, well-characterized biospecimen repositories to support genomic research, biomarker discovery, and the creation of personalized treatment strategies. Robotic biobanking systems facilitate this growth by automating the handling, storage, and retrieval of samples, ensuring accuracy, efficiency, and scalability as sample volumes rise. For example, in July 2025, UK Biobank Limited, a UK-based large-scale biomedical database, announced plans to relocate over 11 million samples to its new Manchester headquarters in 2026. The facility will house four next-generation automated freezers capable of storing up to 20 million samples, with robotic systems retrieving approximately 1 million samples annually - four times faster than the current capacity. As a result, the rising volume of biological sample collections is propelling the growth of the robotic biobanking systems market.

Leading companies in the robotic biobanking systems market are focusing on strategic collaborations to enhance technological capabilities, expand service accessibility, and accelerate the adoption of automation in advanced biobanking workflows. Such collaborations involve partnerships between technology providers, healthcare institutions, and research organizations to leverage complementary strengths, foster innovation, improve operational efficiency, and increase market reach. For instance, in October 2025, Abu Dhabi Biobank, a UAE-based hybrid cord blood bank, partnered with NMC Healthcare, a UAE healthcare provider, to expand access to private and public cord blood banking services across major hospitals in the region. The collaboration supports personalized healthcare and stem cell research through the integration of robotic and automated biobanking systems. The initiative aims to establish one of the region’s largest cord blood repositories, supported by advanced robotic handling and long-term automated storage technologies, while promoting awareness of the benefits of cord blood preservation and encouraging contributions to future biomedical research and regenerative medicine.

In July 2025, Hamilton Company, a Switzerland-based provider of liquid handling, process analytics, robotics, and automated storage solutions, acquired UK Robotics and Trisonic Discovery for an undisclosed sum. This acquisition enables Hamilton to strengthen its laboratory automation capabilities by integrating advanced scheduling software, system integration expertise, and precision acoustic dispensing technologies to deliver fully automated, scalable research workflows. UK Robotics and Trisonic Discovery are UK-based providers specializing in robotic biobanking systems.

Major companies operating in the robotic biobanking systems market are Thermo Fisher Scientific Inc., Siemens Healthineers AG, Roche Diagnostics Inc., Beckman Coulter Inc., Qiagen N.V., Tecan Group Ltd., Hamilton Company, Azenta Life Sciences, Haier Biomedical Co., BICO, Gilson Inc., SPT Labtech Ltd., B Medical Systems S.a.r.l, MGI Tech Co. Ltd., HighRes Biosolutions Inc., LiCONiC AG, ASKION GmbH, SciRobotics Ltd., Andrew Alliance SA, Angelantoni Life Science Srl.

North America was the largest region in the robotic biobanking systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in robotic biobanking systems report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the robotic biobanking systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The robotic biobanking systems market research report is one of a series of new reports that provides robotic biobanking systems market statistics, including robotic biobanking systems industry global market size, regional shares, competitors with a robotic biobanking systems market share, detailed robotic biobanking systems market segments, market trends and opportunities, and any further data you may need to thrive in the robotic biobanking systems industry. This robotic biobanking systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Robotic biobanking systems are automated, computer-controlled platforms designed to manage, process, and store biological specimens with high precision and minimal human intervention. These systems integrate robotics, artificial intelligence, and data management technologies to ensure accuracy, traceability, and long-term sample integrity within biorepositories. They are primarily used in biomedical research, clinical studies, and pharmaceutical development to streamline specimen handling and improve operational efficiency.

The key product types in robotic biobanking systems include automated sample storage systems, automated sample retrieval systems, automated sample processing systems, and others. Automated sample storage systems are technologically advanced, fully automated units designed to securely store, organize, and retrieve biological specimens with high precision and efficiency under controlled environmental conditions. Sample types include blood, tissue, cells, DNA/RNA, and others, stored across cryogenic, ambient, and refrigerated environments. These systems are used in applications such as clinical research, pharmaceutical and biotech research, academic and research institutions, and biobank management, serving end users including hospitals, research institutes, pharmaceutical and biotechnology companies, and contract research organizations (CROs).

The robotic biobanking systems market consists of sales of automated tube decapping systems, automated capping and recapping systems, robotic plate handling systems, automated liquid handling systems, and sample identification and scanning modules. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.